Norwalk Leslie V 4

What Happened

• Leslie V. Norwalk, a director of Neurocrine Biosciences, was granted a total of 3,908 restricted stock units (RSUs) on May 27, 2026. The grants are derivative awards reported at $0.00 per unit (no cash paid at grant), so the reported dollar value at grant is $0. These RSUs represent a future right to receive common stock upon vesting.

Key Details

• Transaction date: May 27, 2026; Form 4 filed May 29, 2026 (appears timely — within typical two-business-day reporting window).
• Grants: 1,284 RSUs and 2,624 RSUs (total 3,908 RSUs) recorded as acquisition via award (transaction code A) at $0.00.
• Reported value at grant: $0 (RSUs are awards, not purchases).
• Vesting: Footnote F2 states the RSUs will vest in full on May 27, 2027. Footnote F1 explains each RSU equals the right to one share upon vesting.
• Additional footnote (F3) references an option vesting schedule (12 monthly installments beginning June 27, 2026); that appears separate from these RSU grants.
• Shares owned following the transaction were not provided in the supplied data.

Context

• RSU grants are compensatory awards that convert to actual shares only upon vesting; they are not the same as an open-market purchase (which is often viewed as a stronger bullish signal). This filing documents the grant (award) itself. The economic benefit to the insider depends on Neurocrine's stock price when the RSUs vest.